On March 23, 2025, Chengdu Dorher Pharmaceutical Co., Ltd. grandly held its "Staying true to the original aspiration, embarking on a new journey" relocation ceremony at Building 8, No. 99 Haiwang Rd., Wenjiang Dist., Chengdu City.Over a hundred guests from the government, research institutes, industry associations, and strategic partners gathered together to jointly witness this milestone moment.

[Government-Enterprise Collaboration, Jointly Drawing the Blueprint for Development]

At 10:00 AM, the celebration officially kicked off with a magnificent performance of "Drumming for a Prosperous Era." Mr. Li Zhenhua, Director of the Chengdu Medical City Management Committee, Mr. Chang Yongzhi, Minister of the Strategic Research Department, Mr. Huang Jinkun, Chairman of Xiling Lab, Mr. Cui Dexiu, General Manager of Kelun Group Qionglai Branch, Mr. Sun Zhiyuan, Business Vice President of Jincheng Pharmaceutical Group, Ms. Zhu Ni, President of the Bank of China Shuanglin Sub-branch, and other distinguished guests attended the event in person, witnessing the rise of a new force in the regional biopharmaceutical industry. Leaders of the Management Committee stated that DorherPharmaceutical, as a key high-tech enterprise nurtured by Chengdu Medical City, has a full industry chain layout that highly aligns with Wenjiang District's "Three Medical Integration" development strategy. They expressed their expectation that the company, empowered by the new R&D center, will inject stronger momentum into the regional industrial upgrading.

[Tackling Challenging problems, Leading Innovation on Intermediates Synthesis]

In his speech, the company's General Manager, Wei Genghui, warmly recalled the eight-year entrepreneurial journey: developing from a startup team into an innovative enterprise with over 60 professional talents, building a closed-loop full industry chain covering "small-scale R&D, pilot scale &commercial scale production" and cumulatively applying for over 20 invention patents. The company has successively been recognized as a National High-tech Enterprise and a Sichuan Province Specialized and Sophisticated Enterprise with Unique and Novel Products. During the three years of the pandemic, it achieved counter-trend business growth, established deep cooperation with leading enterprises such as Gilead and Kelun Pharmaceutical, demonstrating the resilience of Chinese pharmaceutical enterprises. "The new R&D center is equipped with an intelligent laboratory management system and has already reached strategic cooperation with top teams such as the Chinese Academy of Sciences and Tsinghua University. In the future, we will focus on the research and development of high-difficulty drug molecule fragments, exploring the blue ocean market of innovative drugs with a long-term vision."

[Riding the Same Boat, Jointly Building an Industrial Monument]

Gong Hailing, General Manager of Beijing Xinda Hezong International Trade Co., Ltd., emotionally recounted the eight-year cooperation journey: "Our relationship with Dorheris like the intertwined fate of Nezha and Ao Bing. During the difficult times of the pandemic, our teams stayed up all night talking on the phone to discuss a supply plan for an intermediate of aCOVID-19 drug, and we completed the project successfully with a technological breakthrough in two months, creating a model case for emergency supply guarantee in the industry." Zhu Xu and Wan Jinqiao, representatives of the Wuhan University Alumni Association, highly praised Dorherfrom the perspective of industry-academia-research collaboration, citing its success in tackling the process of Semaglutide excipients and building a collaborative system across three locations: "Chengdu R&D Site- Deyang Pilot Site- Qujing Production Site." They lauded its innovative spirit of "not being a follower, but only a problem solver," and pointed out that the new R&D center will inject triple momentum of technological innovation, project tackling, and regional collaboration into the enterprise, promoting the development of Chengdu's biopharmaceutical industry.

[Cultural Inheritance, Empowering Technological Takeoff]

In the subsequent lion dance segment, the wonderful lion dance performance drew thunderous applause from the audience. During the lion dance eye-dotting ceremony, which was full of traditional cultural charm, the two founders of Dorher Pharmaceutical, Dr. Ning Zhaolun, Vice President of Technology, and Huang Xiangchuan, Vice President of Quality Management, dotted the eyes of the auspicious lions, plucked the greens, and received blessings, symbolizing that DorherPharmaceutical will thrive and have great fortune in its new location. Immediately after, in a warm atmosphere, the leaders and guests went on stage together for the ribbon-cutting ceremony to mark the relocation, signifying the official start of a new chapter of development for DorherPharmaceutical. Subsequently, Mr. Wei Genghui, General Manager, Dr. Ning Zhaolun, Vice President of Technology, Huang Xiangchuan, Vice President of Quality Management, and Li Jianguo, R&D Director, together unveiled the red silk cloth covering the wall behind the indoor reception desk, where the brand new company logo shone brightly.

At the end of the celebration ceremony, General Manager Wei Genghui personally led the guests on a tour of the brand new office building and R&D center, introducing the company's latest developments and future plans. The modern office environment and advanced scientific research equipment left a deep impression on the guests.

The successful holding of this relocation ceremony marks that Chengdu Dorher Pharmaceutical Technology Co., Ltd. has reached a new historical starting point. Looking forward, Dorher Pharmaceutical will continue to take innovation as its engine, continuously improve its R&D strength and industrialization capabilities, and contribute to the progress of China's pharmaceutical industry!